Cerba Research’s Post

How is the Access to Medicine Foundation making a difference? In our latest video, representatives from leading #pharma companies share how the Foundation's work has positively impacted their operations. Through data-driven insights and collaborative efforts, we're changing the industry's engagement with access issues and driving tangible change in #HealthcareAccess. Join us in our mission to ensure that life-saving medications reach those who need them most. Watch the video ➡ https://lnkd.in/eqdZaCna Learn about the impact of our work so far ➡ https://lnkd.in/ehTb8Qgz #AccesstoMedicine #EquitableAccess #AccesstoHealthcare #GlobalHealth

⚕ Today, Curia held its briefing webinar on our Life Sciences Industrial Strategy implementation report for a New Government, bringing together six months of work. Covering themes from governance and implementation, to clinical uptake, adoption and improved population outcomes, we were pleased to be joined by Curia's Health, Care, and Life Sciences Research Group Advisors Dr Keith Ridge CBE Prof. Ann Lloyd Keen and Corinna Bull as well as panellists including: - Michael Lewis (NIHR), - Jim McArdle (IQVIA UK and Ireland ) - Peter Donnelly (Genomics plc) - Helen Dent (British In Vitro Diagnostics Association (BIVDA)) - Chris Lowe (Revvity). The report will be made available to Curia's Health, Care, and Life Sciences Research Group Subscribers, as well as to public sector and third sector professionals. To find out more about becoming a subscriber, email team@curiauk.com. To buy a copy of the report, please find more details here: https://lnkd.in/gmudCkSQ #Health #Care #LifeSciences #NHS #Innovation #Research #Clinical #Clinician #Healthcare #UKPolitics #UKGovernment #ICB #Genomics #HealthTech #MedTech #Medicines #HealthInnovation #Policy #PublicPolicy

Health care is often a “one size fits all” approach because there has been a lack of diversity in medical research. #JoinAllofUs to work towards a better future that represents ALL of us. Get started at JoinAllofUs.org/Together

For those engaged in the healthcare and life sciences sectors, this Spring 2024 edition of Latham's #Healthcare & #LifeSciences Market Update will be of interest. It addresses global regulatory developments affecting life sciences and digital health, as well as the deal drivers and licensing trends of 2024. https://lw.link/m2Yfc5

While the concept of PE is highly acknowledged and promoted, who can take part in the process is restricted via ‘𝗖𝗼𝗻𝗳𝗹𝗶𝗰𝘁 𝗼𝗳 𝗜𝗻𝘁𝗲𝗿𝗲𝘀𝘁’ 𝗽𝗼𝗹𝗶𝗰𝗶𝗲𝘀. 🚫 These policies vary between decision-makers, creating a range of potential barriers to patient participation in decision-making. Participants from different stakeholder groups will be invited to identify practical solutions to navigate the various types of conflict-of-interest policies. But we appreciate your opinion. Leave a comment and let us know what YOU think. ⤵️ 🗣️Valentina Strammiello (European Patients' Forum), Neil Bertelsen (HTAi Patient & Citizen Involvement in HTA Interest Group), Anke-Peggy Holtorf (Outcomes Strategies GmbH), and Finn McCartney (EUPATI). #PEOF

Terrific analysis and recommendations here -- excited to see how the ARPA-H Advancing Clinical Trial Readiness project and ARPANET-H will drive innovation, attract further investment, and help raise these scores #clinicalresearch #clinicaltrials #equitymatters

Strong Public Private Partnerships that include communication, clarity, trust and a sustainable strategy is the key to breaking the all too often rhythm of moving from crisis to complacency!

New PharmaTimes Media Ltd article - penned by Philip Evans and Emma Tonner Primary care has recently been termed the ‘sleeping giant’ of research delivery. But why? Professor Philip Evans says "Primary care is delivering effective and innovative research and has much more to offer." Read the full article to learn more about why studies should be considering primary care for their trial setting: https://lnkd.in/efskpYJG

Exciting news! Our Life Sciences and Healthcare Regulation blog is now live! Discover the latest developments in the Canadian life sciences and healthcare industry: https://bit.ly/3KgbrQN #LegalInsights #LegalBlog #CanadianLaw #LifeSciences

This highlights Cerba Research’s focus. Talk with us and see how we can be your ally in drug development